Chemotherapy for post‐menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function
Cancer Medicine · 2024
DOI: 10.1002/cam4.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Djordje Marina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Breast Neoplasms, Postmenopause, Thyroid Gland. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer (EBC). Among others, weight gain is one of the observed side effects of both chemotherapy and other cancer treatments; however, the mechanism is not well‐described. In this study, we aimed to assess thyroid function before and shortly after the course of chemotherapy for EBC.
Methods
This is a prospective cohort study of women diagnosed with EBC. The main outcome was the thyroid function and body weight before and after completing chemotherapy. Secondary outcomes were the presence of thyroid autoantibodies and treatment radiation dosage. We included 72 patients treated with adjuvant chemotherapy, whereas 59 patients also received supraclavicular locoregional radiotherapy. Triple‐negative breast cancer (BC) patients receiving chemoimmunotherapy were excluded.
Results
After the chemotherapy, we observed an increase in thyroid‐stimulating hormone ( p = 0.03) and a decrease in free‐thyroxine ( p = 0.0006), with no significant weight change. The prevalence of autoimmune thyroiditis was low. On average 3 months post‐chemo, we found no statistically significant difference in the thyroid function of women treated versus not treated with supraclavicular locoregional radiotherapy.
Conclusions
Although statistically significant changes in thyroid hormones were observed, this study suggests no obvious clinically significant changes in thyroid function in women with early BC after the course of chemotherapy. The decrease in thyroid function was not related to autoimmunity, non‐thyroidal illness, radiotherapy, or high‐dose corticosteroids. Further studies with a longer follow‐up of thyroid function after adjuvant chemotherapy and supraclavicular locoregional radiotherapy are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Djordje Marina
Zitieren
APA
Marina, D., Buch-Larsen, K., Gillberg, L., Andersen, M. A., Andersson, M., Rasmussen, Å. K., & Schwarz, P. (2024). Chemotherapy for post‐menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function. Cancer Medicine. https://doi.org/10.1002/cam4.70015
Vancouver
Marina D, Buch-Larsen K, Gillberg L, Andersen MA, Andersson M, Rasmussen ÅK, et al. Chemotherapy for post‐menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function. Cancer Medicine. 2024. doi:10.1002/cam4.70015
BibTeX
@article{Marina2024,
author = {Marina, Djordje and Buch-Larsen, Kristian and Gillberg, Linn and Andersen, Mads Albrecht and Andersson, Michael and Rasmussen, Åse Krogh and Schwarz, Peter},
title = {Chemotherapy for post‐menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70015}
}
EUVIMED